The present invention relates to novel compounds and their use as fragrance materials.

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R.sup.1 to R.sup.9 have meanings as defined in the Specification, are useful as estrogen receptor ligands. ##STR00001##

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R.sup.1 to R.sup.9 have meanings as defined in the Specification, are useful as estrogen receptor ligands. ##STR00001##

The present disclosure relates to compounds of Formula (I): ##STR00001##
and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

This invention relates to deuterated aryl-anthracene compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.

This invention relates to deuterated aryl-anthracene compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.

A P2X.sub.4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster-associated pain in acute phase: ##STR00001##
wherein R.sup.1 is hydrogen, a C.sub.1-8 alkyl group, or the like; each of R.sup.2 and R.sup.3 is hydrogen, a C.sub.1-8 alkyl group, or the like; each of R.sup.4 and R.sup.5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

A P2X.sub.4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster-associated pain in acute phase: ##STR00001##
wherein R.sup.1 is hydrogen, a C.sub.1-8 alkyl group, or the like; each of R.sup.2 and R.sup.3 is hydrogen, a C.sub.1-8 alkyl group, or the like; each of R.sup.4 and R.sup.5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such as lung disease (e.g., idiopathic pulmonary fibrosis), kidney disease (e.g., chronic kidney disease), or hepatic disease (e.g., non-alcoholic steatohepatitis and portal hypertension).

##STR00001##

A compound of the following formula

##STR00001##

capable of binding to a tripartite motif (TRIM) protein E3 ubiquitin ligase (TRIM21). This application also provides a method for treating a disease associated with abnormal cell proliferation with the compound of formula (I). This application further provides a method for preparing a drug for targeted protein degradation with such compound as an intermediate.